l e t t e r s nature medicine VOLUME 17 | NUMBER 12 | DECEMBER 2011 1 6 4 1 RAF kinases regulate cell proliferation and survival and can be dysregulated in tumors 1,2 . The role of RAF in cell proliferation has been linked to its ability to activate mitogen-activated protein kinase kinase 1 (MEK) and mitogen-activated protein kinase 1 (ERK). Here we identify a MEK-independent role for RAF in tumor growth. Specifically, in mitotic cells, CRAF becomes phosphorylated on Ser338 and localizes to the mitotic spindle of proliferating tumor cells in vitro as well as in murine tumor models and in biopsies from individuals with cancer. Treatment of tumors with allosteric inhibitors, but not ATP-competitive RAF inhibitors, prevents CRAF phosphorylation on Ser338 and localization to the mitotic spindle and causes cell-cycle arrest at prometaphase. Furthermore, we identify phospho-Ser338 CRAF as a potential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade. Mechanistically, CRAF, but not BRAF, associates with Aurora kinase A (Aurora-A) and Polo-like kinase 1 (Plk1) at the centrosomes and spindle poles during G2/M. Indeed, allosteric or genetic inhibition of phosphoSer338 CRAF impairs Plk1 activation and accumulation at the kinetochores, causing prometaphase arrest, whereas a phospho-mimetic Ser338D CRAF mutant potentiates Plk1 activation, mitosis and tumor progression in mice. These findings show a previously undefined role for RAF in tumor progression beyond the RAF-MEK-ERK paradigm, opening new avenues for targeting RAF in cancer.
RAF kinases regulate cell proliferation and survival and can be dysregulated in tumors 1, 2 . The role of RAF in cell proliferation has been linked to its ability to activate mitogen-activated protein kinase kinase 1 (MEK) and mitogen-activated protein kinase 1 (ERK). Here we identify a MEK-independent role for RAF in tumor growth. Specifically, in mitotic cells, CRAF becomes phosphorylated on Ser338 and localizes to the mitotic spindle of proliferating tumor cells in vitro as well as in murine tumor models and in biopsies from individuals with cancer. Treatment of tumors with allosteric inhibitors, but not ATP-competitive RAF inhibitors, prevents CRAF phosphorylation on Ser338 and localization to the mitotic spindle and causes cell-cycle arrest at prometaphase. Furthermore, we identify phospho-Ser338 CRAF as a potential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade. Mechanistically, CRAF, but not BRAF, associates with Aurora kinase A (Aurora-A) and Polo-like kinase 1 (Plk1) at the centrosomes and spindle poles during G2/M. Indeed, allosteric or genetic inhibition of phosphoSer338 CRAF impairs Plk1 activation and accumulation at the kinetochores, causing prometaphase arrest, whereas a phospho-mimetic Ser338D CRAF mutant potentiates Plk1 activation, mitosis and tumor progression in mice. These findings show a previously undefined role for RAF in tumor progression beyond the RAF-MEK-ERK paradigm, opening new avenues for targeting RAF in cancer.
ATP-competitive RAF inhibitors have been shown to have clinical activity in cancers with activating RAF alterations [3] [4] [5] [6] [7] [8] . However, in RAS-driven tumors, these agents promote CRAF Ser338 phosphorylation and tumor progression [9] [10] [11] . We previously described an allosteric inhibitor of RAF (compound 6, referred to here as KG5) that does not compete for ATP but does inhibit phospho-Ser338 CRAF and tumor growth 12 .
KG5 had growth-inhibitory activity against the various lines in the NCI-60 panel (Supplementary Table 1 ), suggesting that KG5 influences a mechanism that is independent of RAS or RAF activation status. Tumor cells exposed to KG5 appeared rounded and arrested in mitosis, whereas cells treated with ATP-competitive RAF or MEK inhibitors maintained adhesion and progression through mitosis ( Supplementary Figs. 1a and 2) . KG5 inhibited phospho-Ser338 CRAF, causing mitotic arrest at prometaphase followed by cell death in multiple tumor cell lines (Supplementary Figs. 1a,b,d ,e, 2 and 3), similar to the effects of paclitaxel. As is true for most kinase-targeted drugs, KG5 also inhibits other targets (for example, the kit oncogene (c-Kit), Fms-related tyrosine kinase 3 (Flt-3) and platelet-derived growth factor receptor (PDGFR)), which might contribute to the antiproliferative effects observed. To address this issue, we tested KG1, a structural analog of KG5 that inhibits the same targets as KG5 except for RAF 12 . KG1 did not inhibit cell proliferation, indicating that the effects of KG5 are a result of RAF inhibition (Supplementary Fig. 1a) .
Phosphorylation of CRAF on Ser338 has been linked to cancer progression [9] [10] [11] [13] [14] [15] . To determine whether KG5 can suppress this activity in vivo, we analyzed orthotopic breast and brain tumor tissues for phospho-Ser338 CRAF before or after systemic delivery of the drug. A single treatment with KG5 led to a qualitative decrease in phosphoSer338 CRAF and an accumulation of cells at prometaphase in both tumor models ( Fig. 1 and Supplementary Fig. 4b) . Notably, although ectopic expression of active MEK did not rescue the effects of KG5 on cell proliferation, cells expressing a phospho-mimetic Ser338D CRAF mutant showed resistance to KG5 (Supplementary Fig. 1c,e) , suggesting that CRAF Ser338 has a MEK-independent role in cell proliferation that can be reversed by an allosteric inhibitor.
We next examined mouse embryonic fibroblasts (MEFs) derived from CRAF-knockout embryos (Raf1 −/− ) 16 . Asynchronized Raf1 −/− MEFs showed a significant increase in the number of cells in G2/M and prometaphase compared to wild-type (WT) MEFs (Fig. 1a and Supplementary Fig. 5a ). After synchronization, Raf1 −/− MEFs accumulated at prometaphase and had a marked delay in mitotic progression (Fig. 1b,c) . Depletion of CRAF in HCT-116 human colon cancer cells similarly led to an accumulation of cells in G2/M (Supplementary Fig. 5e ). Notably, expression of WT CRAF or the kinase-dead (K375M) or phospho-mimetic (S338D) CRAF mutants rescued this mitotic defect, whereas a nonphosphorylatable (S338A) CRAF mutant did not ( Fig. 1d and Supplementary Fig. 5b-d) , even though the S338A mutant maintains kinase activity and can dimerize with BRAF (data not shown). Accordingly, XPA-1 human pancreatic cancer cells expressing WT CRAF completed mitosis in 20 min, whereas cells expressing S338A CRAF completed mitosis in 120 min ( Supplementary Fig. 5f,g ), providing genetic evidence to support a kinase-independent role for phospho-Ser338 CRAF in mitosis.
Furthermore, phospho-Ser338 CRAF amounts were strongly increased in mitosis, during which it co-precipitated with γ-tubulin ( Fig. 2) and, in G2/M, phospho-S338 CRAF localized to the centrosomes and mitotic spindle poles of tumor cells in vitro ( Fig. 2b and Supplementary Fig. 6 ). We also saw this localization in breast cancer tissues from mice and humans ( Fig. 2d and Supplementary  Fig. 7b ). Notably, KG5, but not ATP-competitive RAF inhibitors, prevented this localization (Fig. 2e) . Moreover, in cells treated with the microtubule stabilizing agent paclitaxel, CRAF remained localized to the mitotic spindle, suggesting that KG5 and paclitaxel arrest cells at prometaphase through different mechanisms (Fig. 2e) .
Previous studies showed that CRAF and BRAF can form heterodimers 17 and that BRAF can have a role in mitosis [18] [19] [20] [21] [22] . Notably, although BRAF-CRAF heterodimers can be readily detected in asynchronized cells, we could not detect these heterodimers in mitotic cells (Supplementary Fig. 8c ). In fact, phospho-Ser338 CRAF localized to the spindle pole in cells lacking BRAF (Supplementary Fig. 7a ). These results suggest that the role that CRAF has in mitosis is different from that of BRAF. Mitosis is regulated by various mitotic kinases, such as Aurora kinases, Plk1 and cyclin-dependent kinase 1 (CDK1) [23] [24] [25] . Plk1 is activated by Aurora-A in G2, localizes to centrosomes and spindle poles and accumulates at kinetochores during prometaphase [26] [27] [28] . Accordingly, tumor cells expressing oncogenic RAS are particularly dependent on the activity of Plk1 for mitotic progression and survival 29, 30 , and inhibition or depletion of Plk1 causes cell cycle delay or arrest at prometaphase 27, [31] [32] [33] [34] . Notably, both Aurora-A and Plk1 coprecipitated with CRAF but not with BRAF ( Fig. 3 and Supplementary  Fig. 8) , and CRAF colocalized with Aurora-A and Plk1 at the centrosomes in G2 and at the spindle poles in mitotic tumor cells (Fig. 3b  and Supplementary Fig. 8b) . CRAF, but not BRAF, co-precipitated with Plk1 (Fig. 3c) , and we could detect this co-precipitation in cells expressing either WT or kinase-dead (K375M) CRAF ( Supplementary  Fig. 8d ). However, we detected only minimal amounts of complex in cells expressing the S338A RAF mutant ( Supplementary  Fig. 8a ), suggesting that the interaction between CRAF and Plk1 requires Ser338 phosphorylation but not kinase activity.
Thus, CRAF may serve as a scaffold that brings Aurora-A and Plk1 into a functional mitotic complex.
To determine whether the kinetics of CRAF Ser338 phosphorylation during cell-cycle progression correlated with Plk1 activation, we analyzed CRAF (Ser338) and Plk1 (Thr210) phosphorylation throughout the cell cycle from G1 to M. Amounts of phospho-Ser338 CRAF were increased in G1 but showed a second wave of phosphorylation at G2/M beginning immediately before Plk1 phosphorylation (Fig. 3d) , consistent with the notion that CRAF phosphorylation on Ser338 precedes Plk1 activation. To further explore a possible role for CRAF in Plk1 activation, we subjected lysates from WT and Raf1 −/− MEFs to immunoblotting for phospho-Plk1 or evaluated them for Plk1 enzymatic activity (Fig. 3e and Supplementary Fig. 9a) . Indeed, Raf1 −/− MEFs showed minimal Plk1 activity compared to WT MEFs. Further, tumor cells arrested in prometaphase by KG5 showed decreased Plk1 activity compared to cells arrested by nocodazole or paclitaxel (Supplementary Fig. 9b,c) . Whereas treatment of cells with KG5 had no effect on Plk1 localization to the spindle pole, it did prevent the subsequent accumulation of active Plk1 at the kinetochores (Supplementary Figs. 9d,e and 10 in Raf1 −/− MEFs (Fig. 3f) . We were able to substantiate these findings, as transfection of Raf1 −/− MEFs with the active form of Plk1 (T210D Plk1) rescued the G2/M delay caused by CRAF depletion (Supplementary Fig. 11 ). Together, these results indicate that CRAF potentiates Plk1 or Aurora-A activation, leading to the accumulation of active Plk1 at the kinetochores. This process facilitates mitotic progression through prometaphase and can be blocked by inhibition of phospho-Ser338 CRAF through allosteric RAF blockade.
To investigate the impact of the CRAF-Plk1 signaling module in tumor progression, we evaluated the tumor growth capacity of human colon carcinoma and glioblastoma cells stably expressing the phosphomimetic S338D CRAF mutant. HCT-116 colon cells expressing the S338D CRAF mutant showed accelerated mitosis and a significant increase in tumor growth relative to cells expressing WT CRAF, and this effect was associated with increased expression of phospho-Plk1 but not of phospho-MEK in these tumors (Fig. 4a-e) . Similarly, U-87 glioblastoma cells expressing S338D CRAF showed a significant (P = 0.003) increase in brain tumor growth relative to cells expressing WT CRAF (Supplementary Fig. 12) . Furthermore, cells expressing double-mutant S338D, kinase-dead CRAF (S338D, K375M) also showed increased Plk1 activity and tumor growth in mice but did not activate MEK (Supplementary Fig. 13 ). These results show that phospho-Ser338 CRAF is a key mediator of tumor progression based on its capacity to promote mitosis in a manner that is independent of active MEK.
Although RAF is an essential component of the canonical mitogenactivated protein kinase (MAPK) signaling pathway, various reports have shown that RAF has kinase-independent functions 16, [35] [36] [37] . We previously showed that CRAF, independent of its kinase activity, could translocate to the mitochondria and protect cells from apoptosis by inhibiting the proapoptotic protein ASK1 (refs. 13,14) . Here we report a kinase-independent function of CRAF in cell proliferation and show that phospho-Ser338 CRAF localizes to centrosomes and mitotic spindle poles in G2/M, where it interacts with Aurora-A and Plk1 and promotes Plk1 activation, resulting in mitotic and tumor progression (Supplementary Fig. 14) . Whether CRAF interaction with Aurora-A and Plk1 is direct or indirect remains to be determined. However, these data support the conclusion that CRAF may act as an adaptor protein to promote Aurora-A or Plk1 activation, facilitating mitosis and tumor progression. Although our findings may be relevant to all cells undergoing mitosis, targeting this pathway with allosteric RAF inhibitors, for example, KG5, might be particularly effective during angiogenesis 12 and tumor growth, processes that are characterized by the presence of highly proliferative cells. Finally, our studies show that allosteric inhibitors designed to block phospho-Ser338 CRAF and its function in mitosis are a new therapeutic approach to inhibit the growth of a wide range of cancers.
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